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1. Introduction
Tigecycline, the first of a new class of broad-spectrum 
antibiotics, the glycylcyclines, was recently licensed in South 
Africa for the parenteral treatment of adult patients with 
complicated intra-abdominal infections (cIAIs) and complicated 
skin and soft-tissue infections (cSSTIs). This statement 
addresses important aspects of the new agent, including 
pharmacokinetics, mode of action and antibacterial spectrum, 
summarises key clinical trial data, and highlights  appropriate 
use of the drug. Several other important considerations are also 
briefly addressed.
2. Metabolism and pharmacokinetics
•    Tigecycline undergoes minimal metabolism and is primarily 
excreted by the liver. Additional routes of elimination 
include renal excretion (22%).1,2 
•    Dosing (100 mg loading dose followed by 50 mg 12-hourly) 
is uncomplicated as the agent has no effect on cytochrome 
P450, has no clinically relevant drug interactions, the 
pharmacokinetics (PK) are not influenced by renal 
impairment, and it is not removed by haemodialysis.2
•    In patients with severe hepatic impairment (Child Pugh C), 
the initial dose of tigecycline should be 100 mg followed by 
a reduced maintenance dose of 25 mg every 12 hours. 
•    Tigecycline protein binding is between 71% and 89% 
and the drug demonstrates unusual pharmacokinetics. 
Following multiple doses of 30-minute infusions of 50 
mg given 12-hourly, the following has been documented3 
(comparative PK data with 100 mg are shown in Table I):4 
•    a long terminal half-life (t½) of 42 hours
•    a maximum peak plasma concentration (Cmax ) of 0.87 
mg/l
•    a minimum trough plasma concentration (Cmin ) of 0.13 
mg/l 
•    an AUC from 0 to 24 hours (AUC0-24) of 4.7 mg/h/ml 
•    a high average steady-state volume of distribution (VSS) 
of 639 l. 
This indicates that the drug is widely distributed and 
undergoes extensive and rapid transfer from the blood into the 
tissues, where levels far exceed those of serum (Table II2).
3. Mode of action 
•    Tigecycline binds to the 30S ribosomal subunit, inhibiting 
protein synthesis in a fashion similar to that of the 
aminoglycosides, macrolides and linezolid. 
•    It is generally bacteriostatic except for Streptococcus 
pneumoniae and Legionella spp. where it is bactericidal. 
Tigecycline has a prolonged post-antibiotic effect, ranging 
from 4.9 hours for Escherichia coli to 3.4 - 4 hours for 
Staphylococcus aureus.5 This suggests that it has the potential 
to exert a significant antibacterial effect even when levels 
are below the minimum inhibitory concentration (MIC). 
•    Pharmacodynamic studies have shown that tigecycline 
exhibits time-dependent killing, and as such it has been 
recommended that levels should be maintained above the 
MIC for 50 - 75% of the dosing interval.6 However, because 
of the long half-life and post-antibiotic effect, the area under 
the inhibitory curve (AUC/MIC) has also been shown to be 
most predictive of efficacy.6
•    Tigecycline appears to overcome the major mechanisms 
conferring resistance to the tetracyclines (ribosomal 
protection and efflux pumps) owing to the steric hindrance 
afforded by a large D-ring substitution.1 
•    It is also not affected by common resistance mechanisms 
that affect other antibiotics, such as penicillin-binding 
protein modifications by methicillin-resistant S. aureus 
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tissue infections (cSSTIs). 
Methods. A multidisciplinary meeting representative of the 
Association of Surgeons of South Africa, the Critical Care 
Society of Southern Africa, the Federation of Infectious 
Diseases Societies of Southern Africa, the South African 
Thoracic Society and the Trauma Society of South Africa was 
held to draw up a national guideline for the appropriate use 
of tigecycline. Background information reviewed included 
randomised controlled trials, other relevant publications and 
local antibiotic susceptibility patterns. The initial document 
was drafted at the meeting. Subsequent drafts were circulated 
to members of the working group for modification. 
Output. The guideline addresses several important aspects 
of the new agent, summarising key clinical data and 
highlighting important considerations with the use of the 
drug. The recommendations in this guideline are based on 
currently available scientific evidence together with the 
consensus opinion of the authors.
Conclusion. This statement was written out of concern 
regarding the widespread misuse of antibiotics. Its primary 
intention is to facilitate heterogeneous use of antibiotics as 
a component of antibiotic stewardship and to highlight the 
appropriate use of tigecycline in particular. 
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(MRSA), extended-spectrum β-lactamase (ESBL) production 
by Enterobacteriaceae, carbapenemase production by 
Klebsiella pneumoniae, or DNA gyrase mutations that confer 
fluoroquinolone resistance.2
4. Antibacterial spectrum
•    The Tigecycline Evaluation and Surveillance Trial (TEST), a 
global, multicentre surveillance programme, documented 
that tigecycline is highly active against Gram-positive 
pathogens, including MRSA, methicillin-resistant S. 
epidermidis (MRSE) and enterococci, including vancomycin-
resistant enterococci (VRE).7,8
•    The agent is also highly active against Enterobacteriaceae, 
anaerobes and atypical pathogens.1,2,7,8
•    Reduced activity of tigecycline has been observed for 
Proteus spp., Providencia spp. and Morganella spp., and 
Pseudomonas aeruginosa is also not reliably inhibited by 
tigecycline.1,2
•    There is neither synergy nor antagonism with other 
antibiotics.9
5. Clinical trial data
5.1 Tigecycline has been studied in four phase III double-blind, 
randomised, multicentre comparator clinical studies in adult 
hospitalised patients with cIAI and cSSTI:
•    Tigecycline, in conjunction with operative intervention, 
was shown to be as effective as imipenem/cilastatin in 
treating cIAI, with cure rates in the microbiologically 
evaluable patients identical in the two groups (86%, N=685 
v. 86%, N=679, respectively), and the outcome did not differ 
between monomicrobial versus polymicrobial infections.10
•    Cure rates by clinical diagnosis in the microbiologically 
evaluable population in cIAI are depicted in Fig. 1.
•    Cure rates in clinically evaluable patients hospitalised with 
cSSTI were also similar for those treated with tigecycline 
and those treated with vancomycin plus aztreonam (87%, 
N=422 v. 89%, N=411, respectively).11
•    Cure rates according to underlying co-morbidity and 
concomitant baseline bacteraemia in the clinically evaluable 
population in cases of cSSTI are depicted in Fig. 2. 
5.2 Tigecycline was also evaluated in adults hospitalised with 
community-acquired pneumonia (CAP) in two randomised, 
double-blind, active-controlled, multinational, multicentre 
studies12 with levofloxacin (500 mg IVI once or twice daily) as 
comparator:
•    Microbiological and clinical outcome was similar in the two 
studies, including cases with L. pneumophila infections.
•    An analysis of patients with a higher risk of mortality (age 
≥50 years, pneumonia severity index (PSI) score ≥3 or  
S. pneumoniae bacteraemia) in these two studies also showed 
similar results for clinically evaluable patients; favourable 
outcomes were documented in 89.55% (188/210) and 
81.2% (152/187) in the tigecycline and levofloxacin arms, 
respectively. 
5.3 The agent was also studied in a phase III, open-label, non-
comparative study of the treatment of serious infections due to 
resistant Gram-negative organisms.13 In the microbiologically 
Table I. Pharmacokinetic data for tigecycline4
                  Pharmacological studies 
Parameter      100 mg     50 mg   Efficacy studies 50 mg
Cmax (mg/l)
  30-min infusion    1.45±0.32   0.87±0.23              0.80±0.46 
  60-min infusion    0.90±0.27   0.63±0.10              0.49±0.28 
Cmin (mg/l)    NA   0.13±0.08              0.16±0.09 
Total body clearance (l/h)   21.8±8.9   23.8±7.8              19.9±8.1 
T1/2 (h)     27.1±14.3   42.4±35.3              NA 
AUC24h (mg/l/h)    NA   4.70±1.70              5.85±2.48 
AUC-∞ (mg/l/h)    5.19±1.86   NA              NA 
Fraction unbound (%)   13 - 29   13 - 20              NA 
Volume of distribution (l)   568±244   639±307              NA 
Cmax = maximum peak plasma concentration; Cmin = minimum trough plasma concentration; T½ = terminal half-life; AUC24h = mean single-dose area under the plasma concentration-
time curve at 24 hours; AUC0-∞ = area under the plasma concentration-time curve from 0 hours to infinity; NA = not available.
Table II. Tigecycline distribution in tissue v. serum
Tissue/fluid  Concentration in tissue v. serum
Gallbladder*  38-fold
Colon*   2.3-fold
Skin blister fluid†  26% lower than serum
Alveolar cells†  78-fold
Epithelial lining fluid† 32% greater than serum
Lung*   8.6-fold
Synovial fluid*  0.58-fold
Bone*   0.35-fold
*Patients received a single 100 mg intravenous (IV) dose of tigecycline prior to 
surgery; has not been evaluated in multiple-dose studies.
†Healthy subjects received a single 100 mg IV dose of tigecycline followed by 50 mg 
IV q 12 h.
Reprinted with permission from Peterson.2
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evaluable (ME) population at test of cure (TOC), the clinical 
cure rate was 72.2% (95% confidence interval (CI) 54.8 - 85.8) 
and the microbiological eradication rate was 66.7% (95% CI 
13.7 - 78.8).
5.4 The efficacy of tigecycline compared with vancomycin or 
linezolid for the treatment of serious infections with MRSA 
or VRE was studied in another phase III, multicentre, double-
blind, randomised study.14 For MRSA infections, clinical cure 
rates in the ME patients (N=117) were 81.4% with tigecycline 
and 83.9% (N=31) with vancomycin. In patients with VRE 
(N=15), 3 of 3 ME patients were cured by tigecycline compared 
with 2 of 3 patients by linezolid.
6. Safety and tolerability
•    The most frequent adverse events in all study subjects,  
including tigecycline-treated patients and patients 
receiving comparator therapy, were nausea (30% and 16%, 
respectively) and vomiting (20% and 11%, respectively).10,11
•    No significant difference in discontinuation due to 
treatment-related adverse events was noted between 
tigecycline and all comparators (5% and 4.7%, 
respectively).10,11
7. Other considerations
7.1 Breakpoints for tigecycline susceptibility testing
•    As depicted in Tables IIIa and IIIb, different breakpoints 
for Enterobacteriaceae are recommended by different 
authorities. 
•    As a consequence, published susceptibility rates for  
K. pneumoniae, E. coli and other Enterobacteriaceae differ 
depending on which criteria are used.
•    Similarly conflicting results and discrepancies between 
susceptibility methods have raised the question as to which 
method and which breakpoints should be used when 
reporting Acinetobacter baumannii susceptibility:15-17 
•    Most published studies to date have used a provisional 
breakpoint of ≤2 mg/l.
•    However, the Food and Drug Administration (FDA)18 
and the European Committee on Antimicrobial 
Susceptibility Testing (EUCAST)4 have not made 
recommendations for A. baumannii, and the British 
Society for Antimicrobial Chemotherapy (BSAC) 
has recommended a more conservative breakpoint 
of susceptibility (≤1 mg/l), similar to that of 
Enterobacteriaceae.19
•    Testing for A. baumannii is further complicated by the 
presence of manganese in Mueller-Hinton media, which 
can influence susceptibility results (increases in MIC as 
determined by E-test have been reported).20,21
•    Furthermore, with regard to the Enterobacteriaceae, the 
BSAC recently advised that, owing to a poor correlation 
between MIC and zone diameters for species other than 
E. coli, disc diffusion should not be used and that MIC 
be determined by E-test. Isolates of E. coli that appear 
intermediate or resistant on disc testing need confirmation 
with an MIC.19
7.2 In vitro and in vivo data for tigecycline activity 
against MDR (including carbapenem-resistant) A. 
baumannii
•    Despite the confusion described above, it is expected that 
tigecycline will frequently be used in South Africa (alone 
or in combination) for the treatment of severe A. baumannii 
infections, particularly in critically ill patients.
•    In vitro data derived from 9 of 18 studies reporting on 
multi-drug resistant (MDR) A. baumannii and 7 of 15 
studies reporting specific data on carbapenem-resistant 
Acinetobacter spp. suggested that at least 90% of strains are 
susceptible to tigecycline at an MIC breakpoint of ≤2 mg/l.22 
•    Tigecycline was also active against 9 of 10 polymyxin-
resistant strains and 17 of 17 polymyxin intermediate-
resistant strains.
Fig. 1. Cure rates per clinical diagnosis in the microbiologically evaluable 
population in cases of cIAIs (complicated intra-abdominal infections) 
(reprinted with permission from Babinchak et al.10).
 Fig. 2. Cure rates per underlying co-morbidity and concomitant baseline 
bacteraemia in the clinically evaluable population in cases of cSSTIs (com-
plicated skin and soft-tissue infections) (reprinted with permission from 
Ellis-Grosse et al.11).
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•    These data would, however, represent a serious 
overestimation of the antimicrobial activity of tigecycline 
against MDR Acinetobacter spp. if a more conservative 
breakpoint of ≤1 mg/l was utilised. 
•    With regard to clinical efficacy, very few published data 
are available. Retrospective data compiled from 42 severely 
ill patients (8 of whom were bacteraemic) treated with 
tigecycline showed that tigecycline in combination with 
other antibiotics (mostly polymyxin in 28 patients) was 
effective in 76% (32/42).22 
•    Despite clinical efficacy, tigecycline resistance developed 
during therapy in 3 of the above patients (and was 
associated with clinical failure in 2). In addition, 
breakthrough bacteraemia has been reported in 2 patients 
receiving tigecycline therapy for other infections.22,23 This 
was not surprising as:
•    The MIC90 for A. baumannii in these infections was 2 
mg/l, well above the mean peak serum concentration of 
0.87 mg/l.
•    Acinetobacter spp. are known to have a propensity to 
acquire resistance, and exposure to sub-therapeutic 
serum levels may promote its more rapid emergence.
•    Clinicians should therefore interpret the in vitro activity of 
tigecycline cautiously when using it for off-label indications, 
and treatment should be guided by the MIC.
•    The potential for the development of resistance may also be 
exaggerated by the current registered dose (100 mg loading 
followed by 50 mg 12-hourly) in critically ill patients, as 
the higher volume of distribution in these patients may 
contribute to significant under-dosing (unpublished reports 
have suggested better efficacy at maintenance doses of 100 - 
150 mg 12-hourly).
•    Until further data become available, no firm recommen- 
dations can be made with regard to the testing or clinical 
utility of tigecycline, either alone or in combination with 
polymyxin, the carbapenems (regardless of the mode 
of delivery), rifampicin (or possibly fosfomycin) for 
life-threatening MDR Acinetobacter infections. It would, 
however, seem prudent to use tigecycline at higher doses 
and in combination with other agents in such infections.
7.3 Tigecycline for bacteraemic patients
•    Tigecycline should not be used in primary bacteraemia or 
in infective endocarditis, as it would appear logical that in 
these settings the serum concentration should exceed the 
MIC. Considering that the Cmax is 0.87 mg/l, it would be 
expected that this agent would not be effective. 
•    Bacteraemic infections are, however, usually secondary to 
a primary source and eradication of the source is likely to 
result in clinical resolution.
•    Data from the registration trials in cIAI and cSSTI 
demonstrated equivalent outcome relative to comparators 
in patients with concomitant bacteraemia.10,11 It is important 
to note that no cases of Acinetobacter bacteraemia were 
Table IIIa. USA tigecycline susceptibility breakpoints for different species (FDA)18
              MIC (mg/l)     Zone diameters (mm)
Pathogen     S I R    S I R
S. aureus (incl. methicillin-resistant isolates) ≤0.5* - -    ≥19 - -
Streptococci other than S. pneumoniae  ≤0.25* - -    ≥19 - -
S. pneumoniae    ≤0.06* - -   ≥19 - -
Enterococcus faecalis    ≤0.25* - -    ≥19 - -
Enterobacteriaceae†    ≤2 4 ≥8    ≥19 15 - 18 ≤14
Haemophilus influenzae   ≤0.25* - -   ≥19
Anaerobes‡    ≤4 8 ≥16    N/A N/A N/A
*The current absence of resistant isolates precludes defining any results other than ‘susceptible’.
†Tigecycline has decreased in vitro activity against Morganella spp., Proteus spp. and Providencia spp.
‡Agar dilution.
MIC = minimum inhibitory concentration; S =susceptible; I = intermediately resistant; R = fully resistant; N/A = not available.
Table IIIb. European4 (EUCAST) and British19 (BSAC) tigecycline susceptibility breakpoints for different species
               MIC (mg/l)      Zone diameters (mm)
Pathogen     S I R    S I R
S. aureus     ≤0.5 - >0.5    ≥26 - ≤25
Streptococci other than S. pneumoniae  ≤0.25 0.5 >0.5    ≥25 20 - 24 ≤19
E. faecalis     ≤0.25 0.5 >0.5    ≥21 - ≤20
E. coli     ≤1 2 >2    ≥24 20 - 23 ≤19
Enterobacteriaceae other than E. coli*  ≤1 2 >2    NR NR NR
Enterobacteriaceae other than E. coli†  ≤1 2 >2    ≥24 20 - 23 ≤19
A. baumannii‡    ≤1 2 >2    ≥24 20 - 23 ≤19
*For Enterobacteriaceae other than E. coli, the BSAC do not recommend disc susceptibility testing.
†EUCAST.
‡BSAC.
MIC = minimum inhibitory concentration; S = susceptible; I = intermediately resistant; R = fully resistant; NR = not recommended.
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reported in these studies and no bacteria had an MIC  
≥1 mg/l.10,11
•    Further evidence of efficacy in bacteraemic patients 
emanated from the trial analysis of CAP due to  
S. pneumoniae, and as such tigecycline has been registered 
by the FDA for CAP caused by S. pneumoniae, including 
cases with concurrent bacteraemia.18
•    Recently, pooled results from 8 phase III clinical trials 
comparing the safety and efficacy of tigecycline in subjects 
with secondary bacteraemia were published. Cure rates 
were similar to comparative standard therapies.24
•    The data suggest that tigecycline’s extensive tissue 
distribution allows for eradication of the source of 
secondary bacteraemia.
•    Clinicians should be cautious when using tigecycline for the 
treatment of patients with suspected or proven bacteraemia, 
and use should preferably be guided by the MIC.
7.4 In vitro and in vivo data for tigecycline activity 
against MDR Enterobacteriaceae (ESBL producers or 
carbapenem-resistant (ertapenem and/or imipenem 
and/or meropenem) isolates)25
•    A recent review reported on the in vitro activity of 
tigecycline against ESBL-producing and carbapenem-
resistant Enterobacteriaceae (due to either the new  
K. pneumoniae carbapenemases or metallo-β-lactamases): 
•    Tigecycline was active against >99% of MDR E. coli (N= 
1 936; of which 1 636 strains were ESBL producers and 
14 carbapenem resistant) using either FDA (MIC ≤2 
mg/l) or EUCAST (MIC ≤1 mg/l) susceptibility criteria. 
•    Susceptibility rates for MDR K. pneumoniae were 91.2% 
(N=2 627) and 72.3% (N=1 504) using FDA and EUCAST 
criteria, respectively. For ESBL-producing isolates 
susceptibility was 92.3% (N=2 030) and 72.3% (N=1 284) 
and for carbapenem-resistant strains 94.8% (N=402) and 
71.9% (N=231), respectively.
•    Susceptibility rates for ESBL-producing Enterobacter 
spp. were 91.3% (N=69) and 77.6% (N=49), and for 
carbapenem-resistant strains 80.3% (N=102) and 57.8% 
(N=102), respectively.
•    Clinical efficacy in infections caused by ESBL-producing 
and carbapenem-resistant Enterobacteriaceae has been 
reported in 33 patients in 10 studies (cIAI and complicated 
pelvic infections N=16, bacteraemia N=8, pulmonary 
infection N=6, urinary tract infection N=3):
•    Outcome was favourable in 69.7% of patients (23/33) 
and classified as uncertain in 3.
•    Tigecycline was administered as monotherapy in 23 
patients and as combination therapy (mostly together 
with polymyxin) in 7.
•    Of note, two recurrences of empyema occurred in 1 
patient with an associated rise in tigecycline MIC (from 
0.75 to 2 mg/l). 
•    Prolonged therapy for microbiological and clinical cure 
(>21 days) was required in 5 cases.
•    It is envisaged that tigecycline will be used in South 
Africa for directed therapy, particularly for carbapenem-
resistant strains, where apart from polymyxin and possibly 
fosfomycin, no alternative Gram-negative antibiotics are 
available.
7.5 In vitro and in vivo data for tigecycline activity 
against Stenotrophomonas maltophilia
•    The majority of clinical isolates of S. maltophilia are 
inherently resistant to most antimicrobial agents, and as 
such few therapeutic options remain.
•    Recent studies have reported the in vitro activity of 
tigecycline against this pathogen: 
•    Tigecycline activity was reported for 131 isolates from 
patients hospitalised in intensive care units (ICUs) in a 
multi-centre, multi-national survey and for 108 isolates 
from ICUs in Canada.26,27
•    In both studies tigecycline and trimethoprim/
sulfamethoxazole were the most active agents, with the 
MIC90 and MIC range reported as 2 and 4 mg/l and 
0.12 - 8 and 0.25 - 16 mg/l, respectively. Applying the 
provisional breakpoint of ≤2 mg/l used by most studies 
to date, 90.1% of strains were susceptible.26 
•    In contrast to the above reports, in which the percentage 
of isolates cultured from blood was not known, 
Livermore et al. recently published the susceptibility of 
S. maltophilia (N=142) isolated from blood cultures in the 
UK and Ireland; 89% were susceptible at a breakpoint of 
≤1 mg/l, with a reported MIC90 of 1 mg/l and an MIC 
range of 0.12 - 4 mg/l.28
•    With regard to clinical efficacy, few data are available. One 
case report described successful treatment of a late-onset 
nosocomial pneumonia caused by an MDR strain of  
S. maltophilia.29
7.6 In vitro and in vivo data for tigecycline activity 
against Clostridium difficile
•    Reported MIC90 values for C. difficile are low, ranging from 
0.06 to 0.25 mg/l.30,31
•    The median faecal concentration of tigecycline is 5.6 mg/l 
(range 3.0 - 14.1 mg/l) after intravenous administration of a 
100 mg loading dose followed by 50 mg twice daily, which 
is significantly higher than that of metronidazole or its 
metabolite (median value 0 mg/l, range 0 - 10.2 mg/l).32,33
•    It has been demonstrated that tigecycline does not induce 
proliferation of the organism or enhance cytotoxin 
production in a human gut model.34
•    The intravenous administration of tigecycline is more 
appealing than oral vancomycin for critically ill patients 
with C. difficile infection (CDI), as gut mobility is often 
impaired and in addition it is questionable whether a 
vancomycin enema can deliver sufficient intra-colonic 
concentrations, particularly to the transverse and ascending 
colon.
•    Successful treatment of severe refractory CDI has recently 
been described in case reports in which conventional 
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therapy with metronidazole or vancomycin had failed 
and colectomy had been considered; all of these patients 
improved within a week and no relapses were observed.35
8. Appropriate use
Tigecycline has been studied as empiric monotherapy in cIAI, 
cSSTI and severe CAP and would be an appropriate option as 
monotherapy for the treatment of patients with cIAI and cSSTI, 
which are the currently registered indications in South Africa, 
in the following circumstances:
8.1 Empiric monotherapy
•    In the elderly or patients with significant co-morbidity 
who have received frequent antibiotic therapy or are from 
long-term care facilities and as such are at risk for resistant 
bacteria such as ESBL-producing strains or polymicrobial 
MDR infections (excluding Pseudomonas spp).
•    Serious and complicated infections due to MRSA and/or 
ESBL-producing infections in patients with established renal 
dysfunction and those at risk of developing renal failure.
•    Where there has been treatment failure with other broad-
spectrum agents despite apparent source control and where 
pseudomonal infection is unlikely.
•    Infections with organisms likely to be susceptible to 
tigecycline in patients with β-lactam allergy. 
•    To facilitate heterogeneous antibiotic use and reduce 
pressure on other agents currently in use as a component of 
antibiotic stewardship. This might be particularly relevant 
for the treatment of ESBL-producing Enterobacteriaceae, 
which has put significant pressure on carbapenems.
8.2 Directed monotherapy
•    Polymicrobial infections with MDR organisms excluding 
Pseudomonas spp., Proteus spp., Providencia spp. and 
Morganella spp. such as serious and complicated infections 
due to mixed infections of MRSA or ESBL-producing 
organisms.
•    MRSA infections in the presence of renal dysfunction as an 
alternative to linezolid. 
•    As such, tigecycline might be a treatment option for hetero-
vancomycin intermediate-resistant (h-VISA, MIC ≥2 mg/l), 
vancomycin intermediate-resistant (VISA, MIC = 8 mg/l) 
and vancomycin-resistant (VRSA, MIC ≥16 mg/l)  
S. aureus infections as well as VRE infections. 
8.3 Directed combination therapy
•    It is uncertain whether tigecycline will be effective with 
more resistant Acinetobacter spp. infections (MICs ≥2 mg/l). 
However, if no other antibiotic is available according to 
susceptibility testing, it may be utilised as salvage therapy 
in combination with other agents. Combinations with 
polymyxin and/or fosfomycin and/or rifampicin have 
mostly been reported, but as has been stated, insufficient 
data exist to make firm recommendations. 
•    If used in these circumstances, pharmacokinetic/
pharmacodynamic data suggest that it should be used at 
higher than the registered dose.
9. Inappropriate use
9.1. Tigecycline is not an appropriate empiric option as 
monotherapy for the treatment of patients with cIAI at risk 
of infection with P. aeruginosa, and in particular those with 
recurrent infection and/or failure of source control.36-39 
9.2 Tigecycline is not an appropriate empiric monotherapy 
option for the treatment of patients with cSSTI where  
P. aeruginosa is a predominant organism, such as chronic 
diabetic foot infection.40
10. Conclusion
This statement has been developed to promote the appropriate 
use of tigecycline in SSTIs and IAIs, which are the current 
registered indications for this antibiotic in South Africa. In 
the USA tigecycline is also registered for CAP, and when 
this indication is registered in South Africa, the statement 
will be updated. Studies are also currently ongoing for other 
indications and in children. 
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